Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Short-term Investments (2022 - 2025)

BioRestorative Therapies (BRTX) has disclosed Short-term Investments for 4 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments fell 66.48% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Sep 2025, down 66.48%, and an annual FY2024 reading of $10.2 million, changed 0.03% over the prior year.
  • Short-term Investments was $3.9 million for Q3 2025 at BioRestorative Therapies, down from $5.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $15.3 million in Q1 2024 and bottomed at $3.9 million in Q3 2025.
  • Average Short-term Investments over 4 years is $10.0 million, with a median of $10.2 million recorded in 2023.
  • The sharpest move saw Short-term Investments skyrocketed 44.83% in 2024, then crashed 66.48% in 2025.
  • Year by year, Short-term Investments stood at $13.0 million in 2022, then fell by 21.89% to $10.2 million in 2023, then grew by 0.03% to $10.2 million in 2024, then plummeted by 61.83% to $3.9 million in 2025.
  • Business Quant data shows Short-term Investments for BRTX at $3.9 million in Q3 2025, $5.8 million in Q2 2025, and $7.9 million in Q1 2025.